Reni Benjamin
Stock Analyst at JMP Securities
(1.32)
# 3,525
Out of 4,962 analysts
173
Total ratings
38.3%
Success rate
-18.07%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.16 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $25.00 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $7.12 | +208.99% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.82 | +144.44% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.36 | +180.90% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $84.76 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.71 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.36 | +194.12% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.43 | +179.72% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $3.03 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.12 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.93 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.06 | +26,129.51% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $17.01 | -41.21% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.35 | +49.25% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $7.65 | +266.01% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $25.86 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $26.27 | +52.26% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.51 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.53 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.27 | +214.96% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.84 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.79 | -8.99% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $48.69 | +23.23% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.44 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $223.39 | +41.01% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $95.16 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $248.48 | +6.65% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.34 | +408.98% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.31 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.97 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.65 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $28.53 | -57.94% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.51 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.16
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $25.00
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $7.12
Upside: +208.99%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.82
Upside: +144.44%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.36
Upside: +180.90%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $84.76
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.71
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.36
Upside: +194.12%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.43
Upside: +179.72%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $3.03
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.12
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.93
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.06
Upside: +26,129.51%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $17.01
Upside: -41.21%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.35
Upside: +49.25%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $7.65
Upside: +266.01%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $25.86
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $26.27
Upside: +52.26%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.51
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.53
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.27
Upside: +214.96%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.84
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.79
Upside: -8.99%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $48.69
Upside: +23.23%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.44
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $223.39
Upside: +41.01%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $95.16
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $248.48
Upside: +6.65%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.34
Upside: +408.98%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.97
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $28.53
Upside: -57.94%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.51
Upside: -